Full Press Release Details
ClearPoint Neuro Reports 53% Increase in 2019 Revenue
revenue grows 41%, fifth consecutive quarter of revenue growth
IRVINE, CA, February 12, 2020 - ClearPoint Neuro,
Inc. (Nasdaq: CLPT) (formerly, MRI Interventions, Inc.; the "Company") today announced financial results for its fourth
fiscal quarter and full year ended December 31, 2019.
2019 Full Year and Fourth Quarter Highlights
"We believe that 2019 exhibited a true inflection
point in our Company's history," commented Joe Burnett, President and CEO of ClearPoint Neuro. "We delivered
growth in all four segments of our business, driven by the performance of our commercial and clinical specialist teams that exceeded
our plan. We made significant progress across our portfolio of navigation and therapy programs that we expect will result in U.S.
FDA submission or market introduction of several new products in 2020, a testament to our development and operations teams. In
transactions completed in May 2019 and January 2020, we secured more than $25 million of financing from strategic partners that
strengthened our balance sheet and facilitated us becoming a Nasdaq-listed company, an accomplishment driven by our finance and
legal teams. The culmination of these successes enabled us to win multiple new biologics and gene therapy partnerships that we
believe will lead to exciting new applications. It is not a coincidence that the totality of these achievements led us to change
our corporate name to ClearPoint Neuro. We feel we are truly a new company, with an exciting future ahead."
Financial Results - Year Ended December
Total revenues were approximately $11.2 million and
$7.4 million for the years ended December 31, 2019 and 2018, respectively, an increase of 53% year-over-year.
Functional neurosurgery revenue, which consists of
disposable product sales related to cases utilizing the ClearPoint system, increased 29% to $6.9 million for 2019, from $5.3 million
in 2018. The increase was due primarily to a record 801 cases utilizing the ClearPoint Neuro Navigation System in 2019, an increase
of 20% from 670 cases in 2018.
Biologics and drug delivery revenue, which include
sales of disposable products and services related to customer-sponsored clinical trials and services, increased 116% to $2.6 million
for 2019, from $1.2 million in 2018. This increase was due primarily to the growth of both clinical services and product sales
5 Musick, Irvine, California 92618 | Phone:
949.900.6833 | www.clearpointneuro.com
Capital equipment sales and related service revenue,
consisting of sales of ClearPoint reusable hardware and software, and related service revenue, increased to $1.7 million for 2019,
from $813,000 in 2018, due primarily to an increase in sales of ClearPoint systems, which historically have varied from quarter
Gross margin for the year ended December 31, 2019 was
66%, as compared to 67% in 2018. The slight decrease was due primarily to an increased contribution from lower margin capital equipment
sales, substantially offset by an increased contribution from sales of services, which bear higher margins relative to other lines
Research and development costs were $2.9 million in
2019, compared to $2.3 million in 2018, an increase of 26%, resulting primarily from increases in product development costs and
departmental compensation. Sales and marketing expenses were $4.8 million for the year ended December 31, 2019, compared to $3.5
million in 2018, an increase of 35%, resulting primarily from increases in incentive-based compensation tied to increased sales
and expansion of the Company's team of clinical specialists. General and administrative expenses were $4.3 million for both
Financial Results - Three Months Ended December 31, 2019
Functional neurosurgery revenue increased 7% to $1.7
million for the three months ended December 31, 2019, from $1.6 million for the same period in 2018. The increase was primarily
due to an expanded customer base and increased utilization by our existing customers of MRI scanner availability.
Biologics and drug delivery revenue increased 99% to
$1.1 million for the three months ended December 31, 2019, from $540,000 for the fourth quarter of 2018.
Capital equipment sales and related service revenue
increased to $446,000 for the three months ended December 31, 2019, versus $174,000 in the fourth quarter of 2018, which, as previously
mentioned, can vary from quarter to quarter.
Gross margin for the three months ended December 31,
2019 was 71%, a slight increase from gross margin of 70% for the same period in 2018, primarily due to an increased contribution
from higher margin services.
Research and development costs were $880,000 for three
months ended December 31, 2019, compared to $481,000 for the same period in 2018, an increase of 83%. Sales and marketing expenses
were $1.5 million for the three months ended December 31, 2019, compared to $879,000 for the same period in 2018, an increase of
72%, attributable primarily to increases in incentive compensation tied to increased sales, and in the expansion of the Company's
team of clinical specialists. General and administrative expenses were $1.3 million for the three months ended December 31, 2019,
compared to $1.2 million for the same period in 2018, an increase of 8%.
Teleconference Information
Investors and analysts are invited to listen to a
live broadcast review of the Company's 2019 fourth quarter and full year financial results today at 4:30 p.m. Eastern time
(1:30 p.m. Pacific time) that may be accessed by visiting the Company's website at www.clearpointneuro.com and
selecting "Investors" / "News" / "IR Calendar." Investors and analysts who would like to
participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside
For those who cannot access the live broadcast, a
replay will be available shortly after the completion of the call until February 26, 2020 by calling (877) 660-6853, or (201)
612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the
broadcast will be available on the Company's website at www.clearpointneuro.com, on the
"Investor Relations" page.
About ClearPoint Neuro
ClearPoint Neuro's mission is to improve and
restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with
pinpoint accuracy. Applications of the Company's current product portfolio include deep-brain stimulation, laser ablation,
biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint Neuro Navigation System
has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States. The Company's SmartFlow
cannula is being used in partnership or evaluation with more than 20 individual biologics and drug delivery companies in various
stages from preclinical research to late stage regulatory trials. To date, more than 3,500 cases have been performed and supported
by the Company's field-based clinical specialist team which offers support and services for our partners. For more information,
please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements herein concerning the Company's plans,
growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding
the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates
or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks
may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular
uncertainties and risks include those relating to: future revenues from sales of the Company's ClearPoint Neuro Navigation
System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's
ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Company's cash resources. More
detailed information on these and additional factors that could affect the Company's actual results are described in the
"Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2018, and
its Quarterly Report on Form 10-Q for the three months ended September 30, 2019, both of which have been filed with the Securities
and Exchange Commission, as well as the Company's Annual Report on Form 10-K for the year ended December 31, 2019, which
the Company intends to file with the Securities and Exchange Commission on or before March 30, 2020.
Harold A. Hurwitz, Chief Financial Officer
Darrow Associates Investor Relations
MRI INTERVENTIONS, INC.
Consolidated Statements of Operations
| Three Months Ended December 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenues: | ||||||||
| Product revenues | $ | 2,523,789 | $ | 1,994,019 | ||||
| Service and other revenues | 686,766 | 282,504 | ||||||
| Total revenues | 3,210,555 | 2,276,523 | ||||||
| Cost of revenues | 933,044 | 689,088 | ||||||
| Research and development costs | 880,334 | 481,293 | ||||||
| Sales and marketing expenses | 1,508,604 | 878,997 | ||||||
| General and administrative expenses | 1,308,630 | 1,206,169 | ||||||
| Operating loss | (1,420,057 | ) | (979,024 | ) | ||||
| Other income (expense): | ||||||||
| Other income (loss), net | 3,229 | (920 | ) | |||||
| Interest expense, net | (228,874 | ) | (237,996 | ) | ||||
| Net loss | $ | (1,645,702 | ) | $ | (1,217,940 | ) | ||
| Net loss per share attributable to common stockholders: | ||||||||
| Basic and diluted | $ | (0.11 | ) | $ | (0.11 | ) | ||
| Weighted average shares outstanding: | ||||||||
| Basic and diluted | 15,165,193 | 11,012,208 |
| Years Ended December 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenues: | ||||||||
| Product revenues | $ | 9,476,364 | $ | 6,685,020 | ||||
| Service and other revenues | 1,740,573 | 668,246 | ||||||
| Total revenues | 11,216,937 | 7,353,266 | ||||||
| Cost of revenues | 3,832,884 | 2,433,069 | ||||||
| Research and development costs | 2,922,279 | 2,310,139 | ||||||
| Sales and marketing expenses | 4,755,516 | 3,532,040 | ||||||
| General and administrative expenses | 4,299,936 | 4,325,786 | ||||||
| Operating loss | (4,593,678 | ) | (5,247,768 | ) | ||||
| Other income (expense): | ||||||||
| Gain on change in fair value of derivative liabilities | - | 64,318 | ||||||
| Other income, net | 9,054 | 364 | ||||||
| Interest expense, net | (955,166 | ) | (980,383 | ) | ||||
| Net loss | $ | (5,539,790 | ) | $ | (6,163,469 | ) | ||
| Net loss per share attributable to common stockholders: | ||||||||
| Basic and diluted | $ | (0.42 | ) | $ | (0.56 | ) | ||
| Weighted average shares outstanding: | ||||||||
| Basic and diluted | 13,155,163 | 10,928,213 |
MRI INTERVENTIONS, INC.
Consolidated Balance Sheets